The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy

References

• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision4th edArlington, VAAmerican Psychiatric Association2000
   Google Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerHJWFSBP Task Force on Treatment Guidelines for SchizophreniaWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerHJWFSBP Task Force on Treatment Guidelines for SchizophreniaWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry20067154016509050
   PubMed Web of Science ®Google Scholar
• MathersCBoermaTFatDMThe Global Burden of Disease: 2004 UpdateGenevaWorld Health Organization2008 Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdfAccessed November 1, 2012
   Google Scholar
• Chinese Society of PsychiatryChinese Classification of Mental Disorders3rd edShandong, ChinaShandong Science and Technology Press2001
   Google Scholar
• World Health OrganizationInternational Statistical Classification of Diseases and Related Health Problems, 10th Revision Version for 2007GenevaWorld Health Organization2007 Available from: http://apps.who.int/classifications/apps/icd/icd10online2007/Accessed September 19, 2012
   Google Scholar
• LambertMKarowALeuchtSSchimmelmannBGNaberDRemission in schizophrenia: validity, frequency, predictors, and patients’ perspective 5 years laterDialogues Clin Neurosci201012339340720954433
   PubMedGoogle Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association, Steering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• SahaSChantDMcGrathJMeta-analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issuesInt J Methods Psychiatr Res2008171556118286464
   PubMed Web of Science ®Google Scholar
• PhillipsMRZhangJShiQPrevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–2005: an epidemiological surveyLancet200937396802041205319524780
   PubMed Web of Science ®Google Scholar
• RanMSXiangMZLiSXPrevalence and course of schizophrenia in a Chinese rural areaAust N Z J Psychiatry200337445245712873330
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMHongJRegional differences in treatment response and three year course of schizophrenia across the worldJ Psychiatr Res201246785686422575332
   PubMed Web of Science ®Google Scholar
• JablenskyASartoriusNErnbergGSchizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country studyPsychol Med Monogr Suppl1992201971565705
   PubMedGoogle Scholar
• BirchwoodMCochraneRMacmillanFCopestakeSKucharskaJCarrissMThe influence of ethnicity and family structure on relapse in first-episode schizophrenia. A comparison of Asian, Afro-Caribbean, and white patientsBr J Psychiatry19921617837901483164
   PubMed Web of Science ®Google Scholar
• CohenAPatelVTharaRGurejeOQuestioning an axiom: better prognosis for schizophrenia in the developing world?Schizophr Bull200834222924417905787
   PubMed Web of Science ®Google Scholar
• PhillipsMRPearsonVLiFXuMYangLStigma and expressed emotion: a study of people with schizophrenia and their family members in ChinaBr J Psychiatry200218148849312456518
   PubMed Web of Science ®Google Scholar
• YangLHApplication of mental illness stigma theory to Chinese societies: synthesis and new directionsSingapore Med J2007481197798517975685
   PubMedGoogle Scholar
• PhillipsMRCharacteristics, experience, and treatment of schizophrenia in ChinaDialogues Clin Neurosci20013210911922033637
   PubMedGoogle Scholar
• ParkLXiaoZWorthJParkJMMental health care in China: recent changes and future challengesHarvard Health Policy Rev2005623545
   Google Scholar
• BlumenthalDHsiaoWPrivatization and its discontents – the evolving Chinese health care systemN Engl J Med2005353111165117016162889
   PubMed Web of Science ®Google Scholar
• LiuJMaHHeYLMental health system in China: history, recent service reform and future challengesWorld Psychiatry201110321021621991281
   PubMed Web of Science ®Google Scholar
• China Statistical Yearbook 2010 [homepage on the Internet]National Bureau of Statistics in ChinaBeijing, ChinaChina Statistics Press2010 Available from: http://www.stats.gov.cn/tjsj/ndsj/2010/indexeh.htm8142012
   Google Scholar
• HungLMRaneSTsaiJShiLAdvancing primary care to promote equitable health: implications for ChinaInt J Equity Health2012111222264309
   PubMed Web of Science ®Google Scholar
• DongKMedical insurance system evolution in ChinaChina Economic Review2009204591597
   Web of Science ®Google Scholar
• LiangDWangQYingX[Analysis on status quo of medical insurance policies on mental disorders in China.]China Health Policy Studies2011474650 Chinese. http://d.wanfangdata.com.cn/periodical_zgwszcyj201107010.aspxAccessed May 20, 2013
   Google Scholar
• RanMXiangMHuangMShanYNatural course of schizophrenia: 2-year follow-up study in a rural Chinese communityBr J Psychiatry2001178215415811157428
   PubMed Web of Science ®Google Scholar
• World Health OrganizationMental health atlas 2005 [webpage on the Internet]GenevaWorld Health Organization2005 Available from: http://www.who.int/mental_health/evidence/mhatlas05/en/Accessed November 2, 2012
   Google Scholar
• PhillipsMRLuSHWangRWEconomic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experienceAm J Psychiatry19971549122812349286181
   PubMed Web of Science ®Google Scholar
• YangSLQianMCLuWCost of treating medical conditions in psychiatric inpatients in Zhejiang, ChinaShanghai Archives of Psychiatry2011236329337
   Google Scholar
• StenslandMWatsonPRGrazierKLAn examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitalsPsychiatr Serv201263766667122588167
   PubMed Web of Science ®Google Scholar
• LowLFDraperBHospitalization patterns for psychiatric disorders across the lifespan in Australia from July 1998 to June 2005Psychiatr Serv200960111311619114581
   PubMed Web of Science ®Google Scholar
• Saz-ParkinsonZMedelACediel-GarcíaPCastelloteJBouzaCAmateJMTrends on schizophrenia admissions during the deinstitutionalisation process in Spain (1980–2004)Soc Psychiatry Psychiatr Epidemiol201146111095110120972771
   PubMed Web of Science ®Google Scholar
• TiihonenJWahlbeckKLönnqvistJEffectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ2006333756122416825203
   PubMed Web of Science ®Google Scholar
• RösslerWSalizeHJvan OsJRiecher-RösslerASize of burden of schizophrenia and psychotic disordersEur Neuropsychopharmacol200515439940915925493
   PubMed Web of Science ®Google Scholar
• AlmondSKnappMFrancoisCToumiMBrughaTRelapse in schizophrenia: costs, clinical outcomes and quality of lifeBr J Psychiatry2004184434635115056580
   PubMed Web of Science ®Google Scholar
• AlonsoJCroudaceTBrownJHealth-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) studyValue Health200912453654319900255
   PubMed Web of Science ®Google Scholar
• CiudadAAlvarezEBobesJSanLPolaviejaPGilaberteIRemission in schizophrenia: results from a 1-year follow-up observational studySchizophr Res20091081–321422219168329
   PubMed Web of Science ®Google Scholar
• MarwahaSJohnsonSSchizophrenia and employment – a reviewSoc Psychiatry Psychiatr Epidemiol200439533734915133589
   PubMed Web of Science ®Google Scholar
• PerlickDARosenheckRAKaczynskiRBinghamSCollinsJAssociation of symptomatology and cognitive deficits to functional capacity in schizophreniaSchizophr Res2008991–319219917851042
   PubMed Web of Science ®Google Scholar
• YeungFKChanSHClinical characteristics and objective living conditions in relation to quality of life among community-based individuals of schizophrenia in Hong KongQual Life Res20061591459146916957873
   PubMed Web of Science ®Google Scholar
• XiangYTWengYZLeungCMTangWKUngvariGSQuality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatologyAust N Z J Psychiatry200741544244917464737
   PubMed Web of Science ®Google Scholar
• XiangYTWangCYWangYSocio-demographic and clinical determinants of quality of life in Chinese patients with schizophrenia: a prospective studyQual Life Res201019331732220135234
   PubMed Web of Science ®Google Scholar
• XiangYTWangCYWengYZPredictors of relapse in Chinese schizophrenia patients: a prospective, multi-center studySoc Psychiatry Psychiatr Epidemiol201146121325133021046070
   PubMed Web of Science ®Google Scholar
• GilesJParkAZhangJWhat is China’s true unemployment rate?China Economic Review2005162149170
   Web of Science ®Google Scholar
• AdvokatCDixonDSchneiderJComatyJEJrComparison of risperidone and olanzapine as used under “real-world” conditions in a state psychiatric hospitalProg Neuropsychopharmacol Biol Psychiatry200428348749515093956
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAWFariesDEKinonBJBakerRWShekharAClinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophreniaSchizophr Bull20083461163117118156640
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETFrewerPAlonsoJJonesPBSOHO Study GroupThe European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatmentActa Psychiatr Scand Suppl200341671512755849
   PubMedGoogle Scholar
• Silva de LimaMde Jesus MariJBreierAMaria CostaAPondé de SenaEHotopfMQuality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychoticsJ Clin Psychiatry200566783183816013897
   PubMed Web of Science ®Google Scholar
• KnappMMangaloreRSimonJThe global costs of schizophreniaSchizophr Bull200430227929315279046
   PubMed Web of Science ®Google Scholar
• ZhaiJGZhaoJPChenJDAn investigation on economic costs of schizophrenia in two medical establishments in Hunan and ShandongChinese Journal of Psychiatry20074014144
   Google Scholar
• China Statistics Press[National Economic and Social Development Statistics Bulletin 2004.] China Statistics http://www.stats.gov.cn/tjgb/ndtjgb/qgndtjgb/t20050228_402231854.htm5202013 Chinese
   Google Scholar
• LangHCSuTPThe cost of schizophrenia treatment in TaiwanPsychiatr Serv200455892893015292543
   PubMed Web of Science ®Google Scholar
• LeeIHChenPSYangYKThe functionality and economic costs of outpatients with schizophrenia in TaiwanPsychiatry Res2008158330631518243334
   PubMed Web of Science ®Google Scholar
• ChangSMChoSJJeonHJEconomic burden of schizophrenia in South KoreaJ Korean Med Sci200823216717518436996
   PubMed Web of Science ®Google Scholar
• WuEQBirnbaumHGShiLThe economic burden of schizophrenia in the United States in 2002J Clin Psychiatry20056691122112916187769
   PubMed Web of Science ®Google Scholar
• GroverSAvasthiAChakrabartiSBhansaliAKulharaPCost of care of schizophrenia: a study of Indian out-patient attendersActa Psychiatr Scand20051121546315952946
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAWFariesDEBallDEKinonBJInvolvement in the US criminal justice system and cost implications for persons treated for schizophreniaBMC Psychiatry2010101120109170
   PubMed Web of Science ®Google Scholar
• AwadAGVorugantiLNPThe burden of schizophrenia on caregivers: a reviewPharmacoeconomics200826214916218198934
   PubMed Web of Science ®Google Scholar
• GarattiniLBarbuiCClementeRCornagoDParazziniFStudy Group SCOREDirect costs of schizophrenia and related disorders in Italian community mental health services: a multicenter, prospective 1-year follow up studySchizophr Bull200430229530215279047
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDErnstFRA comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophreniaAnn Gen Hosp Psychiatry2004311115175112
   PubMedGoogle Scholar
• DaltioCSMariJJFerrazMBDirect medical costs associated with schizophrenia relapses in health care services in the city of São PauloRev de Saude Publica20114511423
   Web of Science ®Google Scholar
• GauSSChungCHGauCSA pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in TaiwanJ Clin Psychopharmacol200828327127818480683
   PubMed Web of Science ®Google Scholar
• WeidenPJOlfsonMCost of relapse in schizophreniaSchizophr Bull19952134194297481573
   PubMed Web of Science ®Google Scholar
• EaddyMGroggALocklearJAssessment of compliance with antipsychotic treatment and resource utilization in a Medicaid populationClin Ther200527226327215811492
   PubMed Web of Science ®Google Scholar
• KnappMKingDPugnerKLapuertaPNon-adherence to antipsychotic medication regimens: associations with resource use and costsBr J Psychiatry2004184650951615172945
   PubMed Web of Science ®Google Scholar
• GuoXZhaiJLiuZEffect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year studyArch Gen Psychiatry201067989590420819983
   PubMed Web of Science ®Google Scholar
• BuchananRWKreyenbuhlJKellyDLSchizophrenia Patient Outcomes Research Team (PORT)The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2010361719319955390
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental HealthSchizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated edition)Leicester, UKThe British Psychological Society and the Royal College of Psychiatrists2010 Available from: http://www.nice.org.uk/nicemedia/live/11786/43607/43607.pdfAccessed September 18, 2012
   Google Scholar
• LeuchtSKisslingWDavisJMSecond-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med200939101591160219335931
   PubMed Web of Science ®Google Scholar
• DossenbachMErolAel Mahfoud KessaciMIC-SOHO Study GroupEffectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidolJ Clin Psychiatry200465331232115096069
   PubMed Web of Science ®Google Scholar
• PrahPPetersenINazarethIWaltersKOsbornDNational changes in oral antipsychotic treatment for people with schizophrenia in primary care between 1998 and 2007 in the United KingdomPharmacoepidemiol Drug Saf201221216116921858898
   PubMed Web of Science ®Google Scholar
• WeinbrennerSAssionHJStargardtTBusseRJuckelGGerickeCADrug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fundPharmacopsychiatry2009422667119308881
   PubMed Web of Science ®Google Scholar
• AnFRXiangYTWangCYChange of psychotropic drug prescription for schizophrenia in a psychiatric institution in Beijing, China between 1999 and 2008Int J Clin Pharmacol Ther201048427027420353748
   PubMed Web of Science ®Google Scholar
• ChongMYTanCHFujiiSAntipsychotic drug prescription for schizophrenia in East Asia: rationale for changePsychiatry Clin Neurosci2004581616714678459
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry201010220059765
   PubMed Web of Science ®Google Scholar
• AmmingerGPEdwardsJBrewerWJHarriganSMcGorryPDDuration of untreated psychosis and cognitive deterioration in first-episode schizophreniaSchizophr Res200254322323011950547
   PubMed Web of Science ®Google Scholar
• LiebermanJAPerkinsDBelgerAThe early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approachesBiol Psychiatry2001501188489711743943
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKHeresSKisslingWDavisJMMaintenance treatment with antipsychotic drugs for schizophreniaCochrane Database Syst Rev20125CD00801622592725
   PubMed Web of Science ®Google Scholar
• Ayuso-GutiérrezJLdel Río VegaJMFactors influencing relapse in the long-term course of schizophreniaSchizophr Res1997282–31992069468354
   PubMed Web of Science ®Google Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• GilmerTPDolderCRLacroJPAdherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophreniaAm J Psychiatry2004161469269915056516
   PubMed Web of Science ®Google Scholar
• LawMRSoumeraiSBRoss-DegnanDAdamsASA longitudinal study of medication nonadherence and hospitalization risk in schizophreniaJ Clin Psychiatry2008691475318312037
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
   PubMed Web of Science ®Google Scholar
• SvarstadBLShiremanTISweeneyJKUsing drug claims data to assess the relationship of medication adherence with hospitalization and costsPsychiatr Serv200152680581111376229
   PubMed Web of Science ®Google Scholar
• PhillipsMRLiYStroupTSXinLCauses of schizophrenia reported by patients’ family members in ChinaBr J Psychiatry2000177202510945083
   PubMed Web of Science ®Google Scholar
• GuoXFangMZhaiJEffectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic studyPsychopharmacology (Berl)2011216447548421369751
   PubMed Web of Science ®Google Scholar
• StroupTSMcEvoyJPSwartzMSThe National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentSchizophr Bull2003291153112908658
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHNyhuisAWStaufferVReasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectivesCurr Med Res Opin201026102403241020812791
   PubMed Web of Science ®Google Scholar
• AttardATaylorDMComparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?CNS Drugs201226649150822668246
   PubMed Web of Science ®Google Scholar
• LahdelmaLAppelbergBClozapine-induced agranulocytosis in Finland, 1982–2007: long-term monitoring of patients is still warrantedJ Clin Psychiatry201273683784222480452
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• HaroJMSuarezDNovickDBrownJUsallJNaberDSOHO Study GroupThree-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies resultsEur Neuropsychopharmacol200717423524417137759
   PubMed Web of Science ®Google Scholar
• OlfsonMAscher-SvanumHFariesDEMarcusSCPredicting psychiatric hospital admission among adults with schizophreniaPsychiatr Serv201162101138114521969639
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDSOHO advisory boardEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• GlickIDCorrellCUAltamuraACMid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approachJ Clin Psychiatry201172121616162722244023
   PubMed Web of Science ®Google Scholar
• WuXLWangJHHuSHTaoJSerum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version)East Asian Arch Psychiatry201222171122447799
   PubMedGoogle Scholar
• ChanHYLinWWLinSKefficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trialJ Clin Psychiatry2007681293617284127
   PubMed Web of Science ®Google Scholar
• ZhangXYZhouDFCaoLYZhangPYWuGYShenYCRisperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind studyInt Clin Psychopharmacol200116632533011712620
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• KomossaKRummel-KlugeCSchwarzSRisperidone versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev20111CD00662621249678
   PubMed Web of Science ®Google Scholar
• LiYMZhaoJPOuJJWuRREfficacy and tolerability of ziprasidone vs olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose studyPharmacopsychiatry201245517718122290206
   PubMed Web of Science ®Google Scholar
• LeeELeungCMWongEAtypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidoneJ Clin Psychiatry200465686486615291666
   PubMed Web of Science ®Google Scholar
• LeeEChowLYLeungCMMetabolic profile of first and second generation antipsychotics among Chinese patientsPsychiatry Res2011185345645820554016
   PubMed Web of Science ®Google Scholar
• AngQTangJZhaoJFactors associated with weight gain during six-month olanzapine therapyChinese Journal of Psychiatry201144316
   Google Scholar
• MontgomeryWTreuerTYeWDoes participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?Proceedings of the 5th ISPOR Asia Pacific ConferenceSeptember 2–4, 2012Taipei, Taiwan http://www.valueinhealthjournal.com/article/S1098-3015%2812%2902106-7/abstractAccessed May 20, 2013
   Google Scholar
• ChenHHPhillipsMRChengHTranslated and annotated version of China’s new Mental Health LawShanghai Archives of Psychiatry2012246305321
   PubMedGoogle Scholar
• HvistendahlMWorld’s biggest health care system goes under the knifeScience2013339611950550723371991
   PubMed Web of Science ®Google Scholar
• Soares-WeiserKBéchard-EvansLLawsonAHDavisJAscher-SvanumHTime to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisEur Neuropsychopharmacol201323211812522633617
   PubMed Web of Science ®Google Scholar